NYSEAMERICAN:MTNB Matinas BioPharma (MTNB) Stock Forecast, Price & News $0.39 +0.01 (+2.48%) (As of 04:33 PM ET) Add Compare Share Share Today's Range$0.38▼$0.4150-Day Range N/A52-Week Range$0.38▼$0.94Volume245,216 shsAverage Volume388,879 shsMarket Capitalization$85.30 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesShort InterestSocial Media Matinas BioPharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside664.1% Upside$3.00 Price TargetShort InterestHealthy0.64% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.11) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Matinas BioPharma has a forecasted upside of 664.1% from its current price of $0.39.Amount of Analyst CoverageMatinas BioPharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.64% of the outstanding shares of Matinas BioPharma have been sold short.Short Interest Ratio / Days to CoverMatinas BioPharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas BioPharma has recently decreased by 14.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MTNB. Previous Next 2.2 News and Social Media Coverage News SentimentMatinas BioPharma has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Matinas BioPharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Matinas BioPharma is held by insiders.Percentage Held by InstitutionsOnly 12.84% of the stock of Matinas BioPharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Matinas BioPharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas BioPharma is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas BioPharma is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas BioPharma has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Matinas BioPharma (NYSEAMERICAN:MTNB) StockMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.Read More Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MTNB Stock News HeadlinesMay 30, 2023 | americanbankingnews.comMatinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest UpdateMay 12, 2023 | seekingalpha.comMatinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.8MJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 12, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Matinas BioPharma (MTNB)May 12, 2023 | msn.comRecap: Matinas BioPharma Hldgs Q1 EarningsMay 11, 2023 | msn.comWhy Matinas BioPharma Stock Is Sinking TodayMay 11, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finance.yahoo.comQ1 2023 Matinas BioPharma Holdings Inc Earnings CallJune 1, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.May 11, 2023 | finance.yahoo.comMatinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023May 10, 2023 | finance.yahoo.comMatinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue EstimatesMay 10, 2023 | finance.yahoo.comMatinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 3, 2023 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023April 28, 2023 | proactiveinvestors.comMatinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drugApril 23, 2023 | benzinga.comCTI BioPharma Stock (NASDAQ:CTIC), Analyst Ratings, Price Targets, PredictionsApril 19, 2023 | msn.comMatinas jumps 25% to hit four-month high on data for anti-fungal agentApril 18, 2023 | finance.yahoo.comCompassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMIDMarch 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and MoonLake Immunotherapeutics (MLTX)March 19, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2022 Financial Results and Provides a Business UpdateMarch 18, 2023 | seekingalpha.comMatinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | insidermonkey.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Spruce Biosciences (SPRB)March 16, 2023 | finance.yahoo.comQ4 2022 Matinas BioPharma Holdings Inc Earnings CallMarch 15, 2023 | finance.yahoo.comMatinas BioPharma Reports 2022 Financial Results and Provides a Business UpdateMarch 14, 2023 | msn.comEarnings Outlook For Matinas BioPharma HldgsMarch 8, 2023 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023March 2, 2023 | finance.yahoo.comMatinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMIDSee More Headlines MTNB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTNB Company Calendar Last Earnings3/15/2023Today6/01/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MTNB CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+683.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,000,000.00 Net Margins-479.18% Pretax Margin-479.16% Return on Equity-54.49% Return on Assets-44.87% Debt Debt-to-Equity RatioN/A Current Ratio14.88 Quick Ratio14.88 Sales & Book Value Annual Sales$3.19 million Price / Sales26.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book2.55Miscellaneous Outstanding Shares217,260,000Free Float197,277,000Market Cap$83.23 million OptionableNot Optionable Beta2.03 Key ExecutivesJerome D. JabbourPresident, Chief Executive Officer & DirectorKeith A. KucinskiChief Financial OfficerRaphael J. ManninoChief Scientific Officer & Senior Vice PresidentJames J. FergusonChief Medical OfficerHui LiuChief Technology OfficerKey CompetitorsTiziana Life SciencesNASDAQ:TLSADaré BioscienceNASDAQ:DAREParatek PharmaceuticalsNASDAQ:PRTKXilio TherapeuticsNASDAQ:XLOvTv TherapeuticsNASDAQ:VTVTView All CompetitorsInstitutional OwnershipJane Street Group LLCSold 147,123 shares on 5/16/2023Ownership: 0.027%BlackRock Inc.Sold 248,183 shares on 5/12/2023Ownership: 1.136%Renaissance Technologies LLCBought 50,833 shares on 5/12/2023Ownership: 0.079%Private Advisor Group LLCBought 195,283 shares on 5/10/2023Ownership: 0.090%Global Retirement Partners LLCSold 39,000 shares on 5/8/2023Ownership: 0.046%View All Institutional Transactions MTNB Stock - Frequently Asked Questions Should I buy or sell Matinas BioPharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares. View MTNB analyst ratings or view top-rated stocks. What is Matinas BioPharma's stock price forecast for 2023? 2 analysts have issued 12-month target prices for Matinas BioPharma's shares. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 683.1% from the stock's current price. View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts. How have MTNB shares performed in 2023? Matinas BioPharma's stock was trading at $0.5563 at the beginning of 2023. Since then, MTNB stock has decreased by 31.1% and is now trading at $0.3831. View the best growth stocks for 2023 here. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,400,000 shares, a decline of 14.1% from the April 30th total of 1,630,000 shares. Based on an average daily trading volume, of 444,200 shares, the short-interest ratio is presently 3.2 days. View Matinas BioPharma's Short Interest. When is Matinas BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our MTNB earnings forecast. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The company earned $1.06 million during the quarter, compared to analyst estimates of $1.10 million. Matinas BioPharma had a negative trailing twelve-month return on equity of 54.49% and a negative net margin of 479.18%. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS). What is Matinas BioPharma's stock symbol? Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB." Who are Matinas BioPharma's major shareholders? Matinas BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.96%), BlackRock Inc. (1.14%), Private Advisor Group LLC (0.09%), Renaissance Technologies LLC (0.08%), Global Retirement Partners LLC (0.05%) and Modera Wealth Management LLC (0.04%). View institutional ownership trends. How do I buy shares of Matinas BioPharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Matinas BioPharma's stock price today? One share of MTNB stock can currently be purchased for approximately $0.38. How much money does Matinas BioPharma make? Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $83.23 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. How can I contact Matinas BioPharma? Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com. This page (NYSEAMERICAN:MTNB) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.